Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Front Immunol. 2022 Jul 5;13:932155. doi: 10.3389/fimmu.2022.932155. eCollection 2022.
Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells have a deleterious impact on clinical responses to therapeutic antibodies. Myeloid checkpoints, which negatively regulate macrophage and neutrophil anti-tumor responses, are a novel type of checkpoint molecule. Myeloid checkpoint inhibition is currently being studied in combination with IgG-based immunotherapy. In contrast, the combination with IgA-based treatment has received minimal attention. IgA antibodies have been demonstrated to more effectively attract and activate neutrophils than their IgG counterparts. Therefore, myeloid checkpoint inhibition could be an interesting addition to IgA treatment and has the potential to significantly enhance IgA therapy.
免疫疗法中的治疗性抗体在一些患者中由于耐药机制而显示出缺乏持久反应。肿瘤细胞表达的检查点分子对治疗性抗体的临床反应有不良影响。髓系检查点负调控巨噬细胞和中性粒细胞的抗肿瘤反应，是一种新型的检查点分子。髓系检查点抑制目前正在与 IgG 为基础的免疫疗法联合进行研究。相比之下，与 IgA 为基础的治疗联合应用受到的关注较少。已经证明 IgA 抗体比其 IgG 对应物更有效地吸引和激活中性粒细胞。因此，髓系检查点抑制可能是 IgA 治疗的一个有趣补充，并有可能显著增强 IgA 治疗。
